argenx SE (ARGX)
| Market Cap | 54.82B +6.5% |
| Revenue (ttm) | 5.32B +70.3% |
| Net Income | 1.72B +33.9% |
| EPS | 26.21 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 31.96 |
| Forward PE | 30.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 536,450 |
| Open | 847.53 |
| Previous Close | 825.61 |
| Day's Range | 843.51 - 881.10 |
| 52-Week Range | 661.85 - 1,072.75 |
| Beta | -0.04 |
| Analysts | Buy |
| Price Target | 1,152.91 (+32.56%) |
| Earnings Date | Oct 22, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is $1,152.91, which is an increase of 32.56% from the latest price.
News
Citi adds ‘upside 90-day catalyst watch’ on Argenx
Citi added an “upside 90-day catalyst watch” on Argenx (ARGX) while keeping a Buy rating on the shares with a $1,301 price target The company later this quarter will report…
Argenx price target lowered to $1,025 from $1,100 at RBC Capital
RBC Capital lowered the firm’s price target on Argenx (ARGX) to $1,025 from $1,100 but keeps an Outperform rating on the shares. The stock has been volatile lately, “round tripping”…
Argenx reports ALKIVIA study meets primary endpoint
Argenx (ARGX) announced that new data from the Phase 3 study evaluating Vyvgart Hytrulo in patients with autoimmune myositis, focused on immune-mediated necrotizing myopathy, or IMNM, and dermatomyosi...
Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR
Cummins, Argenx and PACCAR offer potential buying opportunities after recent pullbacks, backed by strong earnings growth, improving forecasts and long-term business drivers.
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursda...
ARGX Maintained by Wells Fargo -- Price Target Raised to $1356
ARGX Maintained by Wells Fargo -- Price Target Raised to $1356
Argenx price target raised to $1,356 from $1,355 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,356 from $1,355 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes Q3…
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.
ARGX Maintains by Oppenheimer -- Price Target Lowered to $1038
ARGX Maintains by Oppenheimer -- Price Target Lowered to $1038
Argenx price target lowered to $1,038 from $1,100 at Oppenheimer
Oppenheimer analyst Leland Gershell lowered the firm’s price target on Argenx (ARGX) to $1,038 from $1,100 and keeps an Outperform rating on the shares. The firm is updating its model…
Argenx price target raised to $1,157 from $1,136 at BofA
BofA raised the firm’s price target on Argenx (ARGX) to $1,157 from $1,136 and keeps a Buy rating on the shares. The firm models Q3 Vyvgart revenues of $1.63B, reflecting…
ARGX Maintains Rating by Evercore ISI Group -- Price Target Lowers to $1078
ARGX Maintains Rating by Evercore ISI Group -- Price Target Lowers to $1078
ARGX Maintained by Baird -- Price Target Lowered to $823
ARGX Maintained by Baird -- Price Target Lowered to $823
Argenx price target lowered to $1,140 from $1,250 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Argenx (ARGX) to $1,140 from $1,250 and keeps an Overweight rating on the shares after the company discontinued the Phase 3 UNITY…
Argenx price target lowered to $1,078 from $1,175 at Evercore ISI
Evercore ISI lowered the firm’s price target on Argenx (ARGX) to $1,078 from $1,175 and keeps an Outperform rating on the shares.
Argenx price target lowered to $823 from $932 at Baird
Baird analyst Collen Kusy lowered the firm’s price target on Argenx (ARGX) to $823 from $932 and keeps a Neutral rating on the shares. The firm updated its model following…
Argenx price target lowered to $1,355 from $1,415 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on Argenx (ARGX) to $1,355 from $1,415 and keeps an Overweight rating on the shares. The firm says Sjogren’s disease…
First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo
Wells Fargo raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and keeps an Overweight rating on the shares. With Teva (TEVA) and Argenx (ARGX)…
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.
argenx (ARGX) Reports Mixed Clinical Trial Results, Shares Drop 14%
argenx (ARGX) Reports Mixed Clinical Trial Results, Shares Drop 14%
Argenx has ‘good news and bad news’ day, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao says Argenx (ARGX) is having a “good news and bad news” day. The company announced positive topline results from the 126-patient Phase 2 FB102 study…
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response.
argenx (ARGX) Shares Drop 14.2% Pre-Market Amid Market Uncertainty
argenx (ARGX) Shares Drop 14.2% Pre-Market Amid Market Uncertainty